Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Accounting Officer | January 15, 2026 | January 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date January 15, 2026 · Filed January 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,398 |
Reported balance
After 2026-01-15 transaction · row 1
1 source rowRow 1 · 2026-01-15 · Grant · Acquired 2,398 · Balance 2,398 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 15, 2027, January 15, 2028, January 15, 2029 and January 15, 2030, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $495.88 · Expires 2036-01-15 | Direct | 1,826 |
Reported balance
After 2026-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-15 · Grant · Acquired 1,826 · Balance 1,826 F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 15, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 15, 2027, January 15, 2028, January 15, 2029 and January 15, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 15, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2026 Filed Jan 20, 2026 22:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,826 | $0.00 Strike: $495.88 | $0.00 |
DisclosureSEC source: 0001628280-26-002687 · wk-form4_1768948272.xml · derivative · entry 2 Thakkar Rita · CIK 0002105550 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,826 Underlying: Common Stock · 1,826 shares Expires 2036-01-15 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 15, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 22:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 2,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002687 · wk-form4_1768948272.xml · nonDerivative · entry 1 Thakkar Rita · CIK 0002105550 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,398 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 15, 2027, January 15, 2028, January 15, 2029 and January 15, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.